476
Participants
Start Date
March 26, 2018
Primary Completion Date
March 9, 2020
Study Completion Date
September 15, 2021
avapritinib
Avapritinib tablets for oral administration. Avapritinib will be dosed at 300 mg once daily, continuously.
regorafenib
Regorafenib tablets for oral administration. Regorafenib will be dosed at 160 mg once daily for 3 weeks out of every 4 weeks (ie. 3 weeks on/1 week off).
Memorial Sloan Kettering Cancer Center, New York
UPMC Hillman Cancer Center, Pittsburgh
Fox Chase Cancer Center, Philadelphia
Washington Hospital Center - Oncology and Hematology, Washington D.C.
Duke University Medical Center, Durham
Northside Hospital, Atlanta
Mayo Clinic Cancer Center, Jacksonville
University of Miami, Miami
Moffitt Cancer Center, Tampa
Tennessee Oncology, Nashville
Ohio State University, Columbus
University of Michigan Comprehensive Cancer Center, Ann Arbor
Medical College of Wisconsin - Froedtert Hospital, Milwaukee
Mayo Clinic Cancer Center, Rochester
Northwestern Medicine, Chicago
The University of Chicago Medical Center, Chicago
Washington University in Saint Louis, St Louis
UNICANCER - Lyon, Centre Léon-Bérard, Lyon
USO - Texas Oncology, Dallas
Texas Oncology - Denton South, Denton
Texas Oncology - Waco, Waco
University of Texas MD Anderson, Houston
University of Colorado Hospital, Aurora
Rocky Mountain Cancer Centers, Boulder
Huntsman Cancer Institute, Salt Lake City
Mayo Clinic Cancer Center, Phoenix
UCLA Hematology/Oncology - Santa Monica, Santa Monica
OHSU - Knight Cancer Institute, Portland
Fred Hutchinson Cancer Research Center, Seattle
Summit Cancer Centers, Spokane
Dana Farber Cancer Institute, Boston
Flinders Medical Center, Adelaide
Monash Health, Clayton
The Canberra Hospital, Garran
AKH, Klinik f. Innere Med. I, Onkologie, Vienna
Institut Jules Bordet, Brussels
Leuven Cancer Institute, Leuven
Cross Cancer Institute, Edmonton
Jewish General Hospital, Montreal
Beijing Cancer Hospital, Beijing
Chinese PLA General Hospital, Beijing
West China Hospital Sichuan University, Chengdu
The First Affiliated Hospital of Chongqing Medical University, Chongqing
Fujian Medical University Union Hospital, Fuzhou
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou
The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou
The First Affiliated Hospital, Zhejiang University, Hangzhou
Harbin Medical University Cancer Hospital, Harbin
The First Affiliated Hospital of Nanchang Medical University, Nanchang
Guangxi Medical University Affiliated Tumor Hospital & Oncology Medical College, Nanning
The Affiliated Hospital of Qingdao University, Qingdao
Fudan University Shanghai Cancer Center, Shanghai
Fudan University Zhongshan Hospital, Shanghai
Shanghai Jiaotong University School of Medicine, Renji Hospital, Shanghai
Liaoning Cancer Hospital & Institute, Shenyang
Tianjin Cancer Hospital, Tianjin
Affiliated Cancer Hospital of Xinjiang Medical University, Ürümqi
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Onkologická klinika Fakultní nemocnice Olomouc, Olomouc
Fackultni Nemocnice v Motole, Prague
Institut Bergonié, Bordeaux
Centre Oscar Lambret, Lille
Institute Paoli Calmettes, Marseille
La Timone University Hospital, Marseille
Institut Curie, Paris
Centre Rene Gauducheau, Saint-Herblain
Gustave Roussy Cancer Campus, Villejuif
HELIOS Klinikum Bad Saarow, Bad Saarow
HELIOS Klinikum Berlin-Buch, Berlin
Medizinische Fakultät Carl Gustav Carus, Dresden
Universitaetsklindum Essen, Essen
Universitätsklinikum Frankfurt, Frankfurt
Studienzentrale GbR Lübecker Onkologische Schwerpunktpraxis Dres. med. Uthgenannt, Lübeck
Rupercht-Karls-Universitaet Heidelberg, Mannheim
Fovarosi Onkormanyzat Szent Laszlo Korhaz, Budapest
Magyar Honvédség Egészségügyi Központ Onkológiai Osztály, Budapest
Medical Oncology University Debrecen, Debrecen
University of Pécs, Pécs
Azienda Ospedaliero Universitaria Sant'Orsola Malpighi, Bologna
Candiolo Cancer Institute - FPO, IRCCS, Candiolo
AOUC Azienda Ospedaliero - Universitaria Careggi, Florence
Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Milan
Istituto Europeo di Oncologia, Milan
Universita degli Studi di Palermo - Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone, Palermo
Campus Bio-Medico - Oncology Medica, Roma
Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam
Radboud University Medical Center, Nijmegen
Erasmus Medical Center, Rotterdam
Sanodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwesytecki w Krakowie, Oddzial Kliniczny Onkologii, Krakow
Samodzielny Publiczny Zaklad Opieki Zdrowotnej MSWiA z W-MCO, Olsztyn
Maria Skodowska Curie Memorial Cancer Centre and Institute of Oncology, Warsaw
Dolnoslaskie Centrum Onkologii we Wrocawiu, Wroclaw
National Cancer Centre Singapore, Singapore
Ajou University Hospital, Suwon
Asan Medical Center, Seoul
Samsung Medical Center, Seoul
Seoul National University Hospital, Seoul
Severance Hospital, Seoul
Hospital de la Santa Creu i Sant Pau, Barcelona
Institut Català d'Oncologia - Hospital Duran i Reynals, Barcelona
Vall d'Hebron, Barcelona
Hospital La Paz, Madrid
Hospital Universitario Gregorio Marañón, Madrid
Hospital Universitario Puerta de Hierro, Madrid
Hospital Virgen del Rocio, Seville
Fundacion Instituto Valenciano de Oncologia, Servicio de Oncologia, Valencia
Hospital Universitario Miguel Servet, Zaragoza
Skanes University Hospital, Lund
Beatson West of Scotland Cancer Centre, Glasgow
Guy's Hospital, London
The Christie NHS Foundation Trust, Manchester
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield
University Health Network, Toronto
The Royal Marsden Hospital, London
Lead Sponsor
Blueprint Medicines Corporation
INDUSTRY